#Canada #Laval #Bausch Health #Salix Pharmaceuticals #Cirrhosis Care

Improvement in Cirrhosis Management Through Standardized Pathway

Bausch Health Companies Inc., alongside its gastroenterology division, Salix Pharmaceuticals, recently unveiled notable outcomes from a six-month pilot study aimed at enhancing the management of cirrhosis. The study, which was implemented in five community gastroenterology practices, focused on evaluating a standardized clinical pathway designed to foster adherence to guideline-based care for patients battling cirrhosis. This initiative was pivotal in addressing the inconsistencies in treatment strategies that often occur across different clinical environments.

Cirrhosis is a serious liver condition associated with high morbidity rates and intensive healthcare requirements. However, the approaches taken by healthcare professionals to manage the disease can greatly differ, resulting in a gap in optimal patient care. This study sought to provide a structured pathway by merging insights from both academic and community healthcare providers. It emphasized the importance of sticking to current clinical guidelines and evidence-based practices.

During the pilot study, researchers employed population health analytics to assess adherence to five vital performance indicators. These included monitoring follow-up office visits, laboratory tests, the use of nonselective beta-blockers for patients with varices, the treatment of hepatic encephalopathy, and enrollment in chronic care management programs. With a total of 4,251 cirrhosis patients included in the analysis, the study revealed the following improvements:

• - Office Visit Adherence: This metric rose from 46.9% at the start of the study to 51.1%, showcasing a 9% relative enhancement.
• - Laboratory Monitoring Adherence: Similarly, this adherence increased from 61.5% to 63.5%, representing a 3.2% relative improvement.
• - Non-Selective Beta-Blocker Treatment: For patients diagnosed with varices, the treatment rate showed a modest increase from 47.2% to 48.8%.
• - Medication for Hepatic Encephalopathy: Treatment compliance increased from 60.2% to 64.9%, marking a significant 7.8% improvement.
• - Chronic Care Management Enrollment: There was a notable rise in enrollment from 11.7% to 12.8%, a 9.4% relative boost.

The lead investigator, Dr. Peng-Sheng (Brian) Ting, noted that the results underscore the essential nature of clinical pathways in providing consistent, evidence-based care for cirrhosis patients. With the increasing prevalence of liver diseases, employing proven care pathways is crucial for bridging care gaps, ensuring adherence to treatment, and ultimately enhancing patient outcomes. The study utilized the advanced Cardinal Health PPS Analytics platform, allowing investigators to detect care gaps and measure adherence to predefined benchmarks effectively.

Together, these findings advocate for broader adoption of standardized clinical pathways in managing cirrhosis within community settings. The outcomes highlighted the feasibility and positive impact of implementing such frameworks, reinforcing their potential to facilitate better adherence to treatment guidelines and support healthcare providers in delivering optimal care.

In conclusion, as the healthcare community strives for improved care solutions, this pilot study serves as a significant step toward implementing structured approaches in cirrhosis management, which can ultimately enhance patient health outcomes in a scalable manner.

About Bausch Health

Bausch Health Companies Inc. is a global pharmaceutical organization dedicated to improving health outcomes. It oversees a diverse product portfolio primarily focused on gastroenterology through Salix Pharmaceuticals, one of the largest specialty pharmaceutical businesses. For more information about their initiatives and products, visit Bausch Health's website and follow them on LinkedIn.